All In Biotech

Drug Trial Radar · NCT06830850

A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Jun 15, 2025

Primary completion

Dec 30, 2026

Study completion Mar 15, 2027

Sponsor

Lead sponsor
Atridia Pty Ltd.Industry
Sponsor type
Industry
First posted
Feb 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of 5041-103 in Subjects with Metastatic Castration-resistant Prostate Cancer.

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

  • HRS-5041 Single dose of HRS-5041 orally administeredDrug

    HRS-5041 Oral dosage (Tablet) Oral dosage administration, 28 days per cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events, ECOG PS score, vital signs (pulse rate, respiratory rate, blood pressure, body temperature), ECG, clinical chemistry, hematology, urinalysis and physical examinationTime frame: Screening up to study completion, an average of 1 year.

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Icon Cancer Centre South Brisbane

    Brisbane, Australia

  • John Flynn Private Hospital

    Brisbane, Australia

  • Eastern Health (Box Hill Hospital)

    Melbourne, Australia

  • Linear Clinical Research Ltd

    Perth, Australia

  • Macquarie University

    Sydney, Australia

  • MUPharm Pty Limited trading as Macquarie University Hospital Pharmacy

    Sydney, Australia

  • Illawarra Shoalhaven Local Health District (Wollongong Hospital)

    Wollongong, Australia

  • GenesisCare North Shore (Oncology)

    Sydney, New South Wales, Australia

  • Sydney Adventist Hospital

    Sydney, New South Wales, Australia

  • Cancer Research SA

    Adelaide, South Australia, Australia

  • Southern Oncology Clinical Research Unit

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.